The AdvantaTM IO Gene Expression Assay is part of a complete workflow that focuses on 170 genes to enable tumor immunobiology profiling and new biomarker identification. Designed to meet the rigorous demands of human checkpoint inhibitor research programs, the Advanta IO Gene Expression Assay includes 91 key markers of tumor immune response that were shown in a multicenter international clinical trial to inform tumor progression and checkpoint therapeutic response. Follow the link below to learn more about the assay and its advantages.
Learn More